CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
BI 10773 +2 moredrug
Likely dose
Gemfibrozil 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01301742
NCT01301742Phase 1Completed

Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial

Boehringer Ingelheim·interventional·Posted Feb 23, 2011·Updated Jun 18, 2014

In Brief

A Phase 1 clinical trial evaluating BI 10773 and Gemfibrozil for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

To investigate the relative bioavailability of BI 10773 following coadministration with 600 mg gemfibrozil bid dosed to steady-state in comparison to BI 10773 when given alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 23, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.4 years ago

Interventions

BI 10773drug

1 tablet single dose BI 10773 in the morning

Gemfibrozildrug

Gemfibrozil 600 mg bid for 5 days

BI 10773drug

1 tablet single dose BI 10773 in the morning